OX40L/TNFSF4 Protein, Human, Recombinant (hFc)

Catalog No. TMPY-04832 Copy Product Info

OX40L/TNFSF4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.6 kDa.

OX40L/TNFSF4 Protein, Human, Recombinant (hFc)

Catalog No. TMPY-04832

Copy Product Info

OX40L/TNFSF4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.6 kDa.

Pack Size	Price	USA Stock	Global Stock
5 μg	$42	-	In Stock
10 μg	$65	7-10 days	7-10 days
20 μg	$98	7-10 days	7-10 days
50 μg	$197	-	In Stock
100 μg	$346	7-10 days	7-10 days
200 μg	$612	7-10 days	7-10 days
500 μg	$1,300	7-10 days	7-10 days

Add to Cart

Add to Quotation

For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Resource Download

COA User Guide of Recombinant Proteins

Product Information

Biological Activity	1.Loaded Recombinant Human OX40 Ligand/TNFSF4 Protein, hFc Tag (Cat#TMPY-04832) on ProA Biosensor, can bind Recombinant Human OX40/TNFRSF4 Protein, His Tag (Cat#TMPY-01423) with an affinity constant of 0.909 μM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 2.Immobilized Recombinant Human OX40 Protein (His & Avi Tag), Biotinylated (Cat#TMPY-06906) at 1 μg/mL (100 μL/well) on Streptavidin precoated (5 μg/mL, 100 μL/well) plate can bind Recombinant Human OX-40L/TNFSF4/CD252 Protein (Fc Tag) (Cat#TMPY-04832), the EC50 is 2.0-6.0 ng/mL (Routinely tested).
Description	OX40L/TNFSF4 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 46.6 kDa.
Species	Human
Expression System	HEK293 Cells
Tag	N-hFc
Synonyms	TXGP1,tumor necrosis factor (ligand) superfamily, member 4,OX4OL,OX-40L,GP34,CD252,CD134L
Construction	A DNA sequence encoding the human TNFSF4 (Gln51-Leu183) was expressed with the Fc region of human IgG1 at the N-terminus. Predicted N terminal: Glu
Protein Purity	> 95 % as determined by SDS-PAGE.
Molecular Weight	46.6 kDa (predicted)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	OX-40L, also known as TNFSF4 and CD252, is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. OX-40L is an important costimulatory molecule that plays a crucial role in the regulation of T-cell-mediated immunity. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. OX-40L is a ligand for receptor TNFRSF4/OX40. It is found to play a role in T cell antigen-presenting cell (APC) interactions. In surface Ig- and CD4-stimulated B cells, this cytokine along with CD7 has been shown to provide CD28-independent costimulatory signals to T cells. This protein and its receptor are reported to directly mediate adhesion of activated T cells to vascular endothelial cells.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy